No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis
- 22 December 2017
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (2) , e105-e107
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma AG
This publication has 7 references indexed in Scilit:
- The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitisJournal of the European Academy of Dermatology and Venereology, 2017
- Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort studyBritish Journal of Dermatology, 2016
- Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral settingBritish Journal of Dermatology, 2016
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisJournal of the American Academy of Dermatology, 2016
- A Review of Psoriasis, Therapies, and SuicideJournal of Cutaneous Medicine and Surgery, 2016
- Brodalumab and suicidal ideation in the context of a recent economic crisis in the United StatesJournal of the American Academy of Dermatology, 2016
- Psoriasis and the Risk of Depression in the US PopulationJAMA Dermatology, 2016